Ganetespib Window of Opportunity Study in Head and Neck Cancers
Stopped Lack of funding
Conditions
- Stage I Hypopharyngeal Squamous Cell Carcinoma
- Stage I Laryngeal Squamous Cell Carcinoma
- Stage I Oral Cavity Squamous Cell Carcinoma
- Stage I Oropharyngeal Squamous Cell Carcinoma
- Stage II Hypopharyngeal Squamous Cell Carcinoma
- Stage II Laryngeal Squamous Cell Carcinoma
- Stage II Oral Cavity Squamous Cell Carcinoma
- Stage II Oropharyngeal Squamous Cell Carcinoma
- Stage III Hypopharyngeal Squamous Cell Carcinoma
- Stage III Laryngeal Squamous Cell Carcinoma
- Stage III Oral Cavity Squamous Cell Carcinoma
- Stage III Oropharyngeal Squamous Cell Carcinoma
- Stage IVA Hypopharyngeal Squamous Cell Carcinoma
- Stage IVA Laryngeal Squamous Cell Carcinoma
- Stage IVA Oral Cavity Squamous Cell Carcinoma
- Stage IVA Oropharyngeal Squamous Cell Carcinoma
Interventions
- DRUG: Ganetespib
- PROCEDURE: Therapeutic Conventional Surgery
- OTHER: Laboratory Biomarker Analysis
Sponsor
Emory University
Collaborators